Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732926 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

475

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin's Lymphomas

Interventions

DRUG: Idelalisib
DRUG: Rituximab
DRUG: Bendamustine
DRUG: Placebo

Sponsor

Gilead Sciences